A New Dawn for IgA Nephropathy – 
 Redefining What is Possible with Sparsentan

A New Dawn for IgA Nephropathy – <br />Redefining What is Possible with Sparsentan

Speakers

• Sydney Tang, MBBS, MD, PhD, MRCP, FRCP, FHKCP, FHKAM
  Chair of Renal Medicine and Yu Professor in Nephrology at The University of Hong Kong
• Nasim Wiegley, MD, FASN
  Nephrology Fellowship Program Director and Director of the Glomerular Disease Clinic at the University of California Davis School of Medicine

Objectives

In this webinar we:

• Described the draft Kidney Disease: Improving Global Outcomes (KDIGO) criteria for risk of disease progression in IgA nephropathy, the proposed target proteinuria levels for preserving kidney function, and the scientific rationale for these proposed proteinuria targets
• Described the clinical benefits of achieving proteinuria remission and how sparsentan may help clinicians achieve these targets
• Evaluated the use of sparsentan in the evolving IgA nephropathy therapeutic landscape in order to better patient outcomes